Advertisement

Topics

Amryt's amendments to EB trial improve the likelihood of success, Shore Capital says

04:42 EDT 17 Apr 2018 | Proactive Investors

Amryt is refining the ongoing P3 trial, increasing the sample size and implementing more strictly defined eligibility criteria, which will cost more money but should, in the view of Shore Capital, enhance the probability of success.

Original Article: Amryt's amendments to EB trial improve the likelihood of success, Shore Capital says

NEXT ARTICLE

More From BioPortfolio on "Amryt's amendments to EB trial improve the likelihood of success, Shore Capital says"

Advertisement
Quick Search
Advertisement
Advertisement